Think Bioscience

Executive Summary

Think Bioscience is a synthetic biology startup founded in 2021 in Boulder, Colorado, that engineers microbes to produce small-molecule drugs targeting historically challenging biological targets. By leveraging the cell's natural chemical processing capabilities, the company's platform enables the discovery of novel mechanisms of biomolecular engagement, potentially unlocking new drug classes for difficult-to-drug targets. While still early-stage and privately held, Think Bioscience's approach combines synthetic biology with drug discovery, positioning it to address unmet needs in areas such as oncology and rare diseases. The company has not disclosed total funding or valuation, but its innovative platform and location in a thriving biotech hub suggest potential for growth. However, with no publicly disclosed pipeline or clinical candidates, the company faces significant technical and financial risks typical of early-stage biotechs.

Upcoming Catalysts (preview)

• 2026Series A Funding Announcement60% success
• 2026Lead Candidate Nomination for First Program50% success
• 2026Academic or Industry Partnership for Platform Validation55% success